TABLE I.
Human TAs that are candidates for immune therapies*
| TA category | Examples |
|---|---|
| Oncofetal | Oncofetal antigen/immature laminin receptor (OFA/iLRP) |
| Glypican 3 (heparan sulfate protoglycan) | |
| α-Fetoprotein (AFP) | |
| Carcinoembryonic antigen (CEA) | |
| Oncogenes | The RAS family: p53, Her2 neu |
| Cancer testis (CT) antigens: | MAGE-1 |
| BAGE | |
| GAGE | |
| NY-ESO-1/LAGE | |
| SAGE | |
| Other 35–40 CT antigens mapping to chromosome X (CT-X) or distributed throughout the genome (non-X CT) | |
| Human melanoma antigens | MART-1/MELAN-A |
| Gp100/pmel 17 | |
| Tyrosinase | |
| Tyrosinase related proteins (TRP) 1 and 2 | |
| Chondroitin sulfate proteoglycan (CSPG4) | |
| Human glioma antigens | IL-13 receptor α2 |
| Eph A2 | |
| Survivin | |
| EGFR variant III (EGFRvIII) | |
| Head and neck cancer antigens | EGFR |
| Human papilloma virus (HPV 16 or 18) | |
| Aldehyde dehydrogenase A1 (ALDHA1) | |
| CSPG4 | |
| Normal overexpressed or modified antigens | MUC-1 |
| Cyclin-B1 | |
| Prostate-specific antigen (pSA) | |
| Prostate membrane-specific Ag (PMSA) |